YK-029A在携带EGFR外显子20插入突变的晚期NSCLC初治患者中的安全性、耐受性、药代动力学及初步疗效:一项1期试验
这项多中心、剂量递增和剂量扩展的1期临床试验评估了第三代EGFR酪氨酸激酶抑制剂YK-029A在携带EGFR突变NSCLC患者中的安全性、耐受性和药代动力学,以及在EGFR外显子20插入突变初治患者中的初步疗效。安全性分析纳入108例患者,未观察到剂量限制性毒性,未达到最大耐受剂量;剂量扩展队列纳入28例初治EGFR外显子20插入突变患者,26例纳入疗效分析,独立评审委员会评估的客观缓解率为73.1%(95%CI 52.21%-88.43%),疾病控制率为92.3%(95%CI 74.87%-99.05%)。
要点
- YK-029A在EGFR突变NSCLC患者中安全性可控、可耐受,未观察到剂量限制性毒性,未达到最大耐受剂量。
- 初治EGFR外显子20插入突变患者中,独立评审委员会评估的客观缓解率为73.1%,疾病控制率为92.3%。
- 常见治疗中出现的不良事件为贫血(50.9%)、腹泻(49.1%)和皮疹(34.3%)。
核心结论
- YK-029A在携带EGFR突变的NSCLC患者中安全性可控且可耐受,在初治EGFR外显子20插入突变患者中显示出有前景的抗肿瘤活性。
研究设计与样本
- 多中心、剂量递增和剂量扩展的1期临床试验,纳入携带EGFR突变的NSCLC患者。
- 剂量递增阶段采用传统3+3原则,YK-029A口服给药,剂量为50、100、150、200和250 mg/d。
- 剂量扩展阶段纳入初治EGFR外显子20插入突变患者,给予YK-029A 200 mg/d。
- 主要终点为安全性和耐受性。
- 安全性分析纳入108例患者;剂量扩展阶段纳入28例初治EGFR外显子20插入突变患者,其中26例纳入疗效分析。
主要发现
- 未观察到剂量限制性毒性,未达到最大耐受剂量。
- 最常见的治疗中出现的不良事件为贫血(50.9%)、腹泻(49.1%)和皮疹(34.3%)。
- 多次给药后药物蓄积极少。
- 独立评审委员会评估的客观缓解率为73.1%(95%CI 52.21%-88.43%),疾病控制率为92.3%(95%CI 74.87%-99.05%)。
关键数值与推荐
- 剂量递增阶段YK-029A口服剂量为50、100、150、200和250 mg/d。
- 剂量扩展阶段YK-029A给药剂量为200 mg/d。
- 客观缓解率73.1%(95%CI 52.21%-88.43%),疾病控制率92.3%(95%CI 74.87%-99.05%),由独立评审委员会评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment options for treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations are limited. This study evaluated the safety, tolerability, and pharmacokinetics of YK-029A, a third-generation EGFR tyrosine kinase inhibitor, and the preliminary efficacy of YK-029A in treatment-naive patients with EGFR ex20ins mutation. METHODS: This multicenter, dose-escalation, and dose-expansion phase 1 clinical trial enrolled patients with NSCLC harboring EGFR mutations. During the dose-escalation phase, YK-029A was orally administered using the traditional 3+3 principle at 50, 100, 150, 200, and 250 mg/d. In the dose-expansion phase, treatment-naive patients with EGFR ex20ins mutations were enrolled and administered YK-029A 200 mg/d. The primary end point was safety and tolerability. RESULTS: The safety analysis included 108 patients. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. The most common treatment-emergent adverse events were anemia (50.9%), diarrhea (49.1%), and rash (34.3%). There was minimal drug accumulation after multiple doses. A total of 28 treatment-naive patients with EGFR ex20ins mutations were enrolled in the dose-expansion and 26 were included in the efficacy analysis. According to the independent review committee evaluation, the objective response rate was 73.1% (95% confidence interval: 52.21%-88.43%), and the disease control rate was 92.3% (95% confidence interval: 74.87%-99.05%). CONCLUSIONS: YK-029A was found to have manageable safety and be tolerable in patients with NSCLC harboring EGFR mutations and have promising antitumor activity in untreated patients with EGFR ex20ins mutations.
引用
- Duan J, Wu L, Yang K, et al. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial. J Thorac Oncol. 2023. PMID: 37776953. doi:10.1016/j.jtho.2023.09.1449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。